ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2016
Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.
Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Pooled it
- Education and Training Needs of U.S. Tuberculosis Programs.Health promotion practice · 2026Article
- Tuberculosis Cases and Deaths Averted by PEPFAR.The New England journal of medicine · 2026Article
- Reply.Arthritis care & research · 2025Article
- Tuberculosis - United States, 2023.MMWR. Morbidity and mortality weekly report · 2024Article
- Cost of inaction: a framework to estimate the economic cost of missing a patient with tuberculosis in the Indian context.BMJ open · 2023Article
- Costs of treating multidrug-resistant TB in California in 2022.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Cost effectiveness analysis of single and sequential testing strategies for tuberculosis infection in adults living with HIV in the United States.Scientific reports · 2022Article
- Article
- Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Health system costs of rheumatic heart disease care in South Africa.BMC public health · 2021Article
- Parallels and Mutual Lessons in Tuberculosis and COVID-19 Transmission, Prevention, and Control.Emerging infectious diseases · 2021Review
- Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas.Pneumonia (Nathan Qld.) · 2020Article
- Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.American journal of respiratory and critical care medicine · 2020Article
- Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.American journal of respiratory and critical care medicine · 2020Article
- Noncountable Tuberculosis Case Reporting, National Tuberculosis Surveillance System, United States, 2010-2014.Public health reports (Washington, D.C. : 1974) · 2020Article
- Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, outcomes, and quality of medical consultations, June 1, 2010 - May 31, 2014.Journal of clinical tuberculosis and other mycobacterial diseases · 2019Article
- Changes in tuberculosis epidemiology, United States, 1993-2017.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019Article
- Not So Fast: Slowing Tuberculosis Decline in California.American journal of public health · 2019Article
- Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.The European respiratory journal · 2018Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byIn reply.2017
Authors and funding
11 authors.
Funding
Abstract
backgroundFollowing a concerted public health response to the resurgence of tuberculosis (TB) in the United States in the late 1980s, annual TB incidence decreased substantially. However, no estimates exist of the number and cost savings of TB cases averted.
methodsTB cases averted in the United States during 1995-2014 were estimated: Scenario 1 used a static 1992 case rate; Scenario 2 applied the 1992 rate to foreign-born cases, and a pre-resurgence 5.1% annual decline to US-born cases; and a statistical model assessed human immunodeficiency virus and TB program indices. We applied the cost of illness to estimate the societal benefits (costs averted) in 2014 dollars.
resultsDuring 1992-2014, 368 184 incident TB cases were reported, and cases decreased by two thirds during that period. In the scenarios and statistical model, TB cases averted during 1995-2014 ranged from approximately 145 000 to 319 000. The societal benefits of averted TB cases ranged from US$3.1 to US$6.7 billion, excluding deaths, and from US$6.7 to US$14.5 billion, including deaths.
conclusionsCoordinated efforts in TB control and prevention in the United States yielded a remarkable number of TB cases averted and societal economic benefits. We illustrate the value of concerted action and targeted public health funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.